Michael H. Buonarati

Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine to intermediates which bind DNA

Michael H. Buonarati, Kenneth W. Turteltaub, Nancy H. Shen et al. · Mutation Research Letters · 1990 · 104 citations

Life Sciences, Biochemistry, Molecular Biology +4

Relationship of cytochrome P450 activity to Clara cell cytotoxicity. II. Comparison of stereoselectivity of naphthalene epoxidation in lung and nasal mucosa of mouse, hamster, rat and rhesus monkey.

Alan R. Buckpitt, Michael H. Buonarati, L B Avey et al. · Journal of Pharmacology and Experimental Therapeutics · 1992 · 99 citations

Medicine, Pharmacology, Toxicology +15

LC–MS/MS Determination of Apixaban (BMS-562247) and its Major Metabolite in Human Plasma: an Application of Polarity Switching and Monolithic HPLC Column

Janice Pursley, Jim X Shen, Alan Schuster et al. · Bioanalysis · 2014 · 59 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +15

Activation of 2-amino-1-methyl-6-phenyimidazo[4,5-<i>b</i>] pyridine (PhIP) to mutagenic metabolites

Michael H. Buonarati, James S. Felton · Carcinogenesis · 1990 · 56 citations

Pharmacy, Biochemistry, Toxicology +13

2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV) (Part 1 – Small Molecules, Peptides and Small Molecule Biomarkers by LCMS)

Eric Yang, Jan Welink, Stephanie Cape et al. · Bioanalysis · 2016 · 48 citations · Full text

Pharmacy, Biochemistry, Biomedical Sciences +17